Franklin Genomic Advancements ETF (HELX)
BATS: HELX · IEX Real-Time Price · USD
32.13
0.71 (2.25%)
At close: May 19, 2022 4:00 PM
32.13
0.00 (0.00%)
After-hours:May 19, 2022 8:00 PM EDT
| Assets | $15.30M |
| NAV | $33.99 |
| Expense Ratio | 0.50% |
| PE Ratio | 21.49 |
| Shares Out | 450,000 |
| Dividend (ttm) | $0.12 |
| Dividend Yield | 0.37% |
| Ex-Dividend Date | Dec 30, 2021 |
| 1-Year Return | -26.76% |
| Volume | 1,293 |
| Open | 35.55 |
| Previous Close | 31.42 |
| Day's Range | 31.11 - 32.23 |
| 52-Week Low | 33.57 |
| 52-Week High | 58.61 |
| Beta | 1.06 |
| Holdings | 52 |
| Inception Date | Feb 25, 2020 |
About HELX
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Asset ClassEquity
RegionGlobal
IssuerFranklin Templeton
Stock ExchangeBATS
Ticker SymbolHELX
Index TrackedSolactive Genomics Index
Top 10 Holdings
42.98% of assets| Name | Symbol | Weight |
|---|---|---|
| Thermo Fisher Scientific | TMO | 6.57% |
| Repligen | RGEN | 5.48% |
| AstraZeneca | AZN | 4.56% |
| Catalent | CTLT | 4.10% |
| Danaher | DHR | 4.02% |
| SAMSUNG BIOLOGICS CO LTD | 207940.KS | 3.82% |
| Bruker | BRKR | 3.82% |
| Agilent Technologies | A | 3.74% |
| Avantor | AVTR | 3.49% |
| Regeneron Pharmaceuticals | REGN | 3.38% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2021 | $0.00394 | Jan 7, 2022 |
| Dec 13, 2021 | $0.11415 | Dec 21, 2021 |
| Dec 14, 2020 | $0.05178 | Dec 23, 2020 |
News
Invest in the Fully Mapped Human Genome With This ETF
Scientists have completed mapping the human genome. New research from the Telomere-to-Telomere (T2T) Consortium, a loose collaborative of about 100 scientists, shows that the team has completed a challe...
1 month ago - ETF Trends